ALTERATION OF PHARMACOKINETIC PARAMETERS OF PROTON PUMP INHIBITORS USING TRANSDERMAL DRUG DELIVERY SYSTEM

M. R. SHIVALINGAM; ARUL BALASUBRAMANIAN; KOTHAI RAMALINGAM

doi:10.22159/ijap.2021v13i5.42617

Authors

M. R. SHIVALINGAM Department of Pharmacy Practice, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation (Deemed to be University), Salem 636008, Tamilnadu, India
ARUL BALASUBRAMANIAN Department of Pharmacy Practice, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation (Deemed to be University), Salem 636008, Tamilnadu, India
KOTHAI RAMALINGAM Department of Pharmacy Practice, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation (Deemed to be University), Salem 636008, Tamilnadu, India

DOI:

https://doi.org/10.22159/ijap.2021v13i5.42617

Keywords:

Transdermal patches, Pantoprazole sodium, Esomeprazole magnesium, Pharmacokinetics

Abstract

Objective: The present study was aimed to find out the effect of transdermal patches of proton pump inhibitors pantoprazole and esomeprazole on the alteration of pharmacokinetic parameters of these drugs.

Methods: The transdermal patches were formulated by the solvent evaporation technique using polymers HPMC E₅ with PVP K 30 and HPMC E₅ with Eudragit L100 in different ratios. The best formulation from each of the drug pantoprazole and esomeprazole was selected and administered to rabbits and the plasma drug concentration was compared with the marketed formulation. The pharmacokinetic parameters such as maximum plasma concentration (C_max), time to reach C_max (t_max), area under the curve (AUC), area under first moment curve (AUMC), elimination rate constant (λ_z), biological half-life (t_1/2), and mean residence time (MRT) were determined.

Results: The plasma drug concentration vs time curve shows the extended-release of the drugs pantoprazole and esomeprazole when compared with the marketed formulation. The results show that there is no change in the peak plasma concentration, but a significant difference was observed in all the pharmacokinetic parameters. The AUC showed 6 fold increase for pantoprazole from 8.91 to 55.20 μg*h/ml and 3.5 fold increase for the drug esomeprazole from 7.86 to 28.53 μg*h/ml, and the mean residence time also showed 2 fold increase for the transdermal patches when compared with the marketed formulations.

Conclusion: The increase in t_max,AUC, and MRT values of the formulated transdermal patches with the values of the marketed formulation of both the drugs, revealed that the transdermal patches can be used to deliver the drug for an extended period and also can alter the pharmacokinetics of pantoprazole and esomeprazole.

Downloads

Download data is not yet available.

References

Asbill CS, Michniak BB. Percutaneous penetration enhancers: local versus transdermal activity. Pharm Sci Technol Today 2000;3:36–41.

Balaji P, Thirumal M, Gowri R, Divya V, Ramaswamy V. Design and evaluation of matrix type of transdermal patches of methotrexate. Int J Pharm Chem Biol Sci 2012;2:464–71.

Das PS, Saha P. Design and characterization of transdermal patches of Phenformin hydrochloride. Int J Curr Pharm Res 2017;9:90–3.

Shivalingam M, Balasubramanian A, Ramalingam K. Non-invasive medicated dermal patch–a review. Int J Pharm Res 2020;12:3018–27.

Shivalingam MR, Balasubramanian A, Ramalingam K. Design and evaluation of medicated dermal patches of proton pump inhibitor-esomeprazole. Int J Pharm Res 2020;12:3038–43.

Funke AP, Schiller R, Motzkus HW, Günther C, Müller RH, Lipp R. Transdermal delivery of highly lipophilic drugs: in vitro fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations. Pharm Res 2002;19:661–8.

Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res 1996;13:1765–9.

Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001;14:101–14.

Madan JR, Dua NSA, K. Formulation and evaluation of transdermal patches of donepezil. Vol. 9. Recent Patents on Drug Delivery and Formulation; 2015. p. 95–103.

Selvaraj GJ, Balasubramanian A, Ramalingam K. Development of the mucoadhesive tablet of pentoxifylline using a natural polymer from Manilkara zapota linn. Int J Appl Pharm 2019;11:88–91.

Selvaraj GJ, Balasubramanian A, Ramalingam K. Application of novel natural mucoadhesive polymer in the development of pentoxifylline mucoadhesive tablets. Int J Appl Pharm 2019;11:37–41.

Huber R, Hartmann M, Bliesath H, Lühmann R, Steinijans VW, Zech K. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996;34:185–94.

Johnson DA. Review of esomeprazole in the treatment of acid disorders. Expert Opin Pharmacother 2003;4:253–64.

Davies JE. The pharmacological basis of therapeutics. Occup Environ Med 2007;64:e2–e2.

Singh A, Bali A. Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride. J Anal Sci Technol 2016;7:1–13.

Shivalingam MR, Arul B, Kothai R. Formulation and evaluation of transdermal patches of pantoprazole sodium. Int J Appl Pharm 2021;13:1.

Prabhakara P, Koland M, Vijaynarayana K, Harish NM, Shankar G, Ahmed MG, et al. Preparation and evaluation of transdermal patches of papaverine hydrochloride. Int J Res Pharm Sci 2010;1:259–66.

Shivaraj A, Selvam RP, Mani TT, Sivakumar T. Design and evaluation of transdermal drug delivery of ketotifen fumarate. Int J Pharm Biomed Res 2010;1:42–7.

Selvaraj GJ, Balasubramanian A, Ramalingam K. Alteration of pharmacokinetic parameters of pentoxifylline using natural mucoadhesive polymers. Int J Appl Pharm 2020;12:153–7.

Harahap Y, Baskara AE, Harmita. Method validation of esomeprazole analysis in human plasma using high-performance liquid chromatography–photodiode array. J Young Pharm 2017;9:s24–8.

Noubarani M, Keyhanfar F, Motevalian M, Mahmoudian M. Improved HPLC method for determination of four PPIs, omeprazole, pantoprazole, lansoprazole and rabeprazole in human plasma. J Pharm Pharm Sci 2010;13:1–10.

Patel BH, Suhagia BN, Patel MM, Patel JR. Determination of pantoprazole, rabeprazole, esomeprazole, domperidone and itopride in pharmaceutical products by reversed-phase liquid chromatography using single mobile phase. Chromatographia 2007;65:743–8.

Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997;17:22–37.

Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+, K+ATPase. Annu Rev Pharmacol Toxicol 1995;35:277–305.

Pue MA, Laroche J, Meineke I, de Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993;44:575–8.

Kamdi SP, Palkar PJ. Bioequivalence study of pantoprazole sodium-HPBCD and conventional pantoprazole sodium enteric-coated tablet formulations. ISRN Pharmacol 2013;2013:347457.

Hassan Alin M, Andersson T, Bredberg E, Röhss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. Eur J Clin Pharmacol 2000;56:665–70.